Participated · Equity · Mar 2026

Mestag Therapeutics develops therapies by leveraging fibroblast immunology to treat cancer and inflammatory diseases. Its pipeline includes MST-0312, a FAP-targeted LTBR agonist bispecific antibody designed to exploit tertiary lymphoid structures in solid tumors, and M402, an agonist antibody targeting a stromal inhibitory receptor for inflammatory disease, alongside earlier discovery-stage programs. The company also uses its RAFT Platform to identify novel fibroblast-immune targets and has entered collaborations with MSD in 2024 and a 2021 agreement with Janssen to discover and license targets. Mestag recently raised $40M in financing to fund the Phase 1 STARLYS clinical study, expected to begin in mid-2026. Leadership includes CEO Susan Hill, with Lindsey Rolfe appointed Chief Medical Officer and Pascal Merchiers appointed Chief Development Officer.

Led · Equity · Jan 2026

VieCure provides Halo Intelligence™, an artificial-intelligence–driven platform that combines structured patient data, a clinical inference engine, and workflow automation to assist oncologists in selecting evidence-based, personalized cancer treatments. Designed as both a smart EMR and real-time decision-support tool, Halo helps reduce clinical complexity, increase guideline-compliant care, and boost practice efficiency. The system is currently used to manage care for nearly 30,000 patients across a growing national network of community oncology locations. Reported outcomes include an approximately eight-fold increase in tumor sequencing rates, a two-fold rise in guideline-aligned treatment plans, and measurable gains in oncologist capacity and workflow productivity. VieCure partners with cancer centers and life-science organizations throughout the United States. Proceeds from its latest financing will be used to expand product capabilities and accelerate market penetration among community oncology practices. Board additions and operational support from investor Mitch Rales’ New Bearing firm aim to instill world-class operating discipline as the company scales.

Led · Equity · Jan 2026

Vizgen develops and commercializes spatial multi-omics technologies that allow scientists to map RNA and protein expression within tissue samples at single-cell resolution. Its flagship MERFISH 2.0 chemistry powers the MERSCOPE Platform, enabling high-throughput, in-situ spatial transcriptomics. Complementing this, the company offers InSituPlex protein assays and the AI-driven STARVUE spatial image-analysis software, creating an integrated workflow for comprehensive tissue profiling. These offerings are intended for research use only and are applied to studying complex diseases such as neurodegenerative disorders and cancer. Vizgen was co-founded by academics Xiaowei Zhuang, David Walt, and Jeffrey Moffitt and is led by CEO Rob Carson. The company operates R&D and lab-services facilities in nearby Cambridge, Massachusetts. With fresh capital in hand, management aims to expand global customer support and scale manufacturing of its platforms. No revenue or user metrics were disclosed in the article.

Participated · Series B · Nov 2025

Elephas Biosciences has built the Elephas Live™ Platform, an ex-vivo, live-tumor-profiling system that maintains a biopsy’s native tumor micro-environment while addressing tumor heterogeneity. The platform functionally characterizes immune response in real time, enabling clinicians to better predict whether a cancer patient will benefit from immunotherapy. With only one in five patients currently responding to immunotherapy, Elephas aims to raise overall response rates and expand patient eligibility by providing more accurate predictive data. The company plans to launch the platform in 2026 as a laboratory developed test (LDT) to accelerate clinical adoption. Recent additions to its Scientific Advisory Board, including Jérôme Galon, Ph.D., and Janis Taube, M.D., signal continued scientific validation efforts. Headquartered in Madison, Wisconsin, Elephas is privately held and backed by a syndicate of life-science investors. The newly secured funding will finance commercialization activities and further technology development.

Participated · Series C · Sep 2025

Octave Bioscience is a commercial-stage precision care company whose flagship product is the Octave MSDA test, a multi-analyte blood-based assay for monitoring MS disease activity. The company reports broad physician adoption with over 325 prescribers, more than 19,000 patient tests delivered to date, and in-network reimbursement covering over 75 million contracted lives at favorable rates. Proceeds from the recent financings will support continued commercialization of the MSDA test and advancement of the company’s Parkinson’s disease pipeline. Octave describes its platform as providing quantitative, clinically actionable insights to improve disease monitoring and treatment decisions. The company also notes a partnership with the Michael J. Fox Foundation on Parkinson’s disease efforts. Octave is based in Menlo Park, Calif. Octave Bioscience is a commercial-stage precision-medicine company that delivers a Precision Care Solution for multiple sclerosis and other neurodegenerative diseases. Its solution includes the Octave MSDA Test, a multivariate blood test for multiple sclerosis, enhanced MRI analytics and protocols, and a clinical care program that connects patients with MS-certified nurse care partners. The Precision Care Solution is currently in use in over 50 clinics across the United States. Octave plans to expand its biomarker-based approach into Parkinson’s disease and will use a $10M grant from The Michael J. Fox Foundation to discover, develop, and validate a custom multiplexed protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic. The company was selected for the MJFF grant based on its track record in biomarker research and prior commercialization of a multiplexed assay panel for multiple sclerosis. Octave combines blood biomarkers, imaging, and clinical insights to provide longitudinal and holistic patient metrics intended to enable informed care, shared decision making, and better patient outcomes. Octave offers a multimodal precision care solution that combines blood biomarkers, expanded MRI analytics, and clinical insights to objectively measure MS disease activity, progression, and severity. Its platform includes the first multivariate blood test for MS disease activity, enhanced imaging protocols, and a clinical care program linking patients with MS nurse practitioners in real time. Octave commercially launched in late 2022 and is in use at multiple MS Centers of Excellence, academic centers, and high-volume independent clinics. The company is expanding physician partnerships and providing capabilities to pharma companies and health plans. Octave is also committed to building collaborations across a broader range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s. Financially, the company announced a $30M extension to its Series B to accelerate commercialization and broaden patient access to its solution. Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with multiple sclerosis (MS). The platform integrates multiple layers of insight: blood-based biomarkers to assess inflammation and immune modulation, advanced MRI readings and interpretation for CNS-level insights, and real-time symptom tracking via mobile tools, sensors and wearables. All data are integrated into protocols, supported by decision‑support tools and presented in a dashboard that enables individual and population views for better stratification and contextual interventions. Octave plans to use these capabilities to provide measurement and management tools for physicians and precision tools and services for pharmaceutical companies to better characterize therapies and optimize pipeline programs. The company emphasizes longitudinal perspectives on disease progression and aims to expand the platform’s applicability across a broad range of neurodegenerative diseases. Octave is headquartered in Menlo Park, California. Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with multiple sclerosis. The platform integrates blood-based biomarkers, enhanced MRI insights, patient monitoring via mobile tools and sensors, and a nurse-led care partner program to produce objective, quantitative measurements. Those measurement layers feed into care pathway models, analytical support systems, decision-support tools and a dashboard to provide longitudinal, population and individual views for clinicians. Octave plans to expand clinical data, initiate early commercial activities, and begin serving neurologists, MS patients and health plans. The company highlights potential application beyond MS to Parkinson’s disease, ALS and Alzheimer’s disease. Octave Bioscience is headquartered in Menlo Park, California.